anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A system and method for organizing and distributing electronic healthcare records (EHRs) copies the EHRs from an EHR database to a separate, remote server computer. The remote server generates viewable and printable electronic documents from the EHRs while omitting information that is not needed by the healthcare professional viewing the electronic documents. Electronic documents for patient appointments in a predetermined window are transferred from the remote server to client computers located in a health care facility. The electronic documents may also be transferred between the client computers to save on network bandwidth from the server computer. The server computer routinely updates the electronic documents based on new EHRs received form the EHR database. Stale electronic documents with out-of-date information are tagged as such.
A two stage, phase I/II, double-blinded, randomized, placebo-controlled study of hepatitis C virus (HCV)uninfected male and female injection drug users (IDU) aged 18 to 45. In this clinical trial AdCh3NSmut1 and MVA-NSMut HCV vaccine will be administered intramuscularly to 68 (+/-4) evaluable volunteers in stage 1. A planned interim analysis of safety and immunogenicity will be conducted based on data through 1 week after receipt of the second vaccination. If no safety signal is detected and there is evidence of a measurable immune response to HCV then an additional 472 (+/-4) volunteers will be enrolled in stage 2. The primary objectives of this study will be 1) to assess the safety of the new candidate hepatitis C virus vaccines, AdCh3NSmut1 and MVA-NSmut, compared to placebo when administered to HCV-uninfected injection drug users (IDUs) and 2) to determine if AdCh3NSmut1 and MVA-NSmut HCV vaccines will reduce incidence of chronic HCV infection compared to placebo among HCV-uninfected IDUs. The secondary objective of this study will be to evaluate the immunogenicity of the new candidate hepatitis C virus vaccines, AdCh3NSmut1 and MVA-NSmut, compared to placebo when administered to HCV-uninfected IDUs.The planned duration of the study is approximately 63 months total including accrual time for subjects (assuming 31 months of screening/enrollments, plus 3 months of halted enrollment for the first interim analysis), 2 months vaccination, 18 months follow-up of each enrolled subject, and 9 months extended observation (monthly), from the time of infection, for subjects becoming viremic in the last month of follow-up.
Two in every 3 Australians will be affected by skin cancer over their lifetime. The prevalence of skin cancer will continue to increase due to the ageing population and represents a significant problem in our community. Cure of early (T1-2) de novo cutaneous squamous cell carcinoma (CSCC) treated with either curative intent surgery or radiotherapy is 85-100%. However, the cure rate for locally advanced, recurrent, or metastatic disease to regional nodes following surgery alone are much lower, in the order of 20-70%. Metastatic CSCC is the most common malignancy of the parotid region in Australia. The 5 year loco-regional control with surgery alone is in the order of 40%-45%. The addition of post-operative radiotherapy improves loco-regional control by 15-20%, and is therefore considered the standard of care in this group of patients.

Recent data have shown that synchronous post-operative chemo-radiotherapy is superior to post-operative radiotherapy alone in "high-risk" mucosal head and neck squamous cell carcinoma (HNSCC). However, to date, there is no evidence from randomised trials that such a benefit exists in CSCC of the head and neck. At present there is little consensus amongst clinicians in Australia as to who should receive post-operative chemo-radiotherapy in CSCC. Although tumour control rates may be improved, the addition of chemotherapy may also significantly increase treatment related toxicity. Nonetheless, some centres have adopted the use of post-operative chemo-radiotherapy in selected patients with CSCC based on extrapolation from mucosal sites. This has resulted in a wide variability in practice for this disease.

Australia is uniquely placed to perform such a trial comparing post-operative chemo-radiotherapy to post-operative radiotherapy alone in high-risk CSCC due to the high rate of skin cancer. Currently there are limited data to guide management of patients with resected CSCC who are at high risk for recurrence. While it is reasonable to hypothesize that concurrent chemotherapy in this setting will confer a similar benefit to that seen in mucosal HNSCC, this can only be established by a randomized trial as proposed. If the addition of chemotherapy is shown to be beneficial and safe, then these results are likely to be translated into standard practice both nationally and internationally quite rapidly. On the other hand, if the treatment is found to be ineffective then patients will be spared the unnecessary toxicity and inconvenience associated with the addition of chemotherapy. A further important aspect of this trial will be the assessment of patient-related outcomes using a validated quality of life questionnaire. It will be important to ascertain whether any improvement in locoregional control due to the addition of chemotherapy, is also associated with improvement in quality of life compared to the control arm.
In the core study, patients received rivastigmine 4.6 mg/24 h daily. For Weeks 1-4, patients received rivastigmine 4.6 mg/24 h. For Weeks 5-24, patients received rivastigmine 4.6 mg/24 h and placebo. No patients received this treatment in the extension study.
The invention discloses an application of a traditional Chinese medicine composition in preparation of potassium ion channel modulator medicine. The traditional Chinese medicine composition is composed of the following traditional Chinese medicine materials in parts by weight: 250-450 parts of coptis chinensis, 150-350 parts of Pinellia ternate, 150-450 parts of Poria cocos, 65-265 parts of immature bitter orange, 150-350 parts of antifebrile dichroa, 10-70 parts of Lotus Plumule, 150-350 parts of radix sophorae flavescentis, 150-350 parts of sweet wormwood, 65-265 parts of ginseng, 150-350 parts of Radix Ophiopogonis and 65-265 parts of liquorice. By adopting the traditional Chinese medicine composition, the myocardial cell action potential duration is prolonged and the refractory period of the myocardiac cell electrical activity is also prolonged. The mechanism of action is capable of restraining the arrhythmia caused by the reentry without toxic or side effect. A new medicine for treating the ventricular, atrial or supraventricular arrhythmia is clinically provided with a good application prospect. The traditional Chinese medicine composition is simple in operation and easy for large-scale production.
A gel composition for improving the efficiency of calculus lithotripsy surgery of the urinary system and assisting in the removal of stone fragments in a kidney collection system. The gel composition comprises component A and component B, wherein component A contains fibrinogen and a fibrin stabilizing factor, and component B contains thrombin. In addition, Ca2+, plasminogen and a coloring agent are added to component A and/or component B. The gel composition may quickly form a plasminogen-containing fibrin gel having a degree of color recognition, and a certain toughness and plasticity in urine and normal saline environments, may adhere to and encapsulate stone fragments in the urine and saline environments, and is removed from the body by using negative pressure suction and/or a stone extraction basket. The gel composition is especially suitable for efficiently removing small stone fragments which remain after calculus lithotripsy and for which there is no effective method for removal at present, has good biosafety, and achieves a stone removal rate of more than 85% without any damage to the collection system and surgical instruments. In addition, the fibrin gel may be naturally dissolved in urine without the risk of urinary system obstruction.
PROBLEM TO BE SOLVED: To obtain the subject cosmetic not generating stick feeling and stiff feeling capable of readily vibrating and mixing separated two layers when used and quickly returning to original state of two layers after using by formulating a polyoxyalkylene adduct, etc., with a cationized polymer. SOLUTION: This cosmetic is obtained by formulating (A) one or two or more kinds of compounds selected from polyoxyalkylene (e.g. polyoxyethylene) adduct of a polyhydric alcohol (e.g. propylene glycol) or a polyhydric alcohol polymer (e.g. dipropylene glycol) and/or a polyoxyethylene-polyoxypropylene copolymer in an amount of 0.5-5 wt.% based on total amount of cosmetic with (B) one or two or more kinds of polymers selected from cationized polymers (e.g. homopolymer of diaryldimethylammonium) in an amount of 0.1-5 wt.% based on total amount of cosmetic and preferably further (C) ethanol in an amount of 1-20 wt.% based on total amount of cosmetic.
ANTHIM should only be used for prophylaxis when its benefit for prevention of inhalational anthrax outweighs the risk of hypersensitivity and anaphylaxis [see Warnings and Precautions (5.1)].

The effectiveness of ANTHIM is based solely on efficacy studies in animal models of inhalational anthrax. It is not ethical or feasible to conduct controlled clinical trials with intentional exposure of humans to anthrax [see Clinical Studies (14)].

Safety and PK of ANTHIM have been studied in adult healthy volunteers. There have been no studies of safety or PK of ANTHIM in the pediatric population. A population PK approach was used to derive intravenous infusion dosing regimens that are predicted to provide pediatric patients with exposure comparable to the observed exposure in adults [see Use in Specific Populations (8.4)].

ANTHIM binds to the protective antigen (PA) component of B. anthracis toxin; it does not have direct antibacterial activity. ANTHIM is not expected to cross the blood-brain barrier and does not prevent or treat meningitis. ANTHIM should be used in combination with appropriate antibacterial drugs.
To better understand the potential for leveraging traditional plant-based ingredients in local fortification efforts in Africa, the proposed study will focus on assessment of acute iron bioavailability in participants consuming instant blended cereal porridges produced using whole grain white maize, with provitamin A (e.g. carrots/mango), moringa leaf powder and baobab fruit powder in specific combinations. The investigators hypothesize that: food-to-food fortified cereal-based porridge with with African baobab fruit and moringa leaf powder will effectively improve iron density and bioavailability in human participants as compared to a "gold standard" fortification (iron sulphate and ascorbic acid).

A randomized crossover design with 4 different white maize cereal-based porridges and a reference control porridge (with matching macronutrient contents) will be used, allowing each participant to serve as their own control. Porridges are designed to specifically compare: (1) Food to food fortification versus standard fortifications and (2) the ability of baobab fruit pulp to enhance iron absorption from both natural and standard sources. The porridges will be composed of locally sourced ingredients including: whole grain white maize, a pro-vitamin A source (oil and available vegetables e.g. carrot and mango) baobab fruit powder and moringa leaf powder.

The enrolled participants will come into the clinic 6 times to consume porridges or have blood drawn. Four times blood (1 for screening, 3 for study) will be drawn to determine the amount of the different forms of iron in participant's blood. On each day of porridge consumption (each visit except the final visit on Day 33), they will consume 2 x 350 g porridge meals and stay 90 mins after the participant has finished each of the meals, and then leave and come back to repeat for a total of 4 hours. After two weeks they will return to the clinic and the investigators will ask to draw some more blood to see if they have absorbed any of the different forms of iron. They will then have the next porridge. Importantly for each visit for both blood draws and the porridge consumption the participants will have to fast the previous night, so no food or beverages like tea or coffee can be consumed (only water allowed). During 5 visits when they will eat two portions of porridge during the day and will have to stay at the facility for 90 mins after each porridge consumption. During the last visit (Day 33), participants will need to give a blood sample, which will take about half an hour. Blood collected during these visits will be used to measure isotopic iron absorbed from the porridges.
BACKGROUND/PURPOSE: Predictive modeling aids in identifying patients at high risk of adverse events. Using routinely collected data, we report a competing risk prediction model for kidney failure.
METHODS: A total of 5138 patients with CKD stages 3b-5 were included and randomized into the development and validation cohorts at a ratio of 7:3. The outcome was end-stage kidney disease, defined as the initiation of dialysis or kidney transplantation. All patients were followed-up until December 31, 2020. A Fine and Gray model was applied to estimate the sub-hazard ratio of kidney failure, with death as a competing event.
RESULTS: In the development cohort, the mean age was 67.6 ± 13.9 years and 60 % were male. The mean index eGFR and median urinary protein-creatinine ratio (UPCR) were 26.5 ± 12.8 mL/min/1.73 m2 and 1051 mg/g, respectively. The median follow-up duration was 1051 days. The proportion of patients with kidney failure and death was 25.4 % and 14.1 %, respectively. Four models were applied, including eGFR, age, sex, UPCR, systolic and diastolic blood pressure, serum albumin, phosphate, uric acid, haemoglobin, and potassium levels had the best goodness of fit. All models had good discrimination with time-to-event c statistics of 0.89-0.95 in the development cohort and 0.86-0.95 in the validation cohort. The prediction models showed excellent and fairly good calibration at 2 and 5-year risk, respectively.
CONCLUSION: Using real-world data, our competing risk model can accurately predict progression to kidney failure over 2 years in patients with advanced CKD.
The present invention discloses a traditional Chinese preparation capable of nourishing the kidney and promoting blood circulation, which can be respectively prepared into powder, pills, oral solutions, medicine wine, etc. according to the requirements of clinics, wherein the traditional Chinese medicine wine is finely prepared from aphrodisiac grass, keel grass, carex brownii tuckerm, etc. as main raw materials to be soaked in rice wine by working procedures of storage, filtration, etc. The preparation organically combines and highly unites a kidney nourishment method and a blood circulation promotion method, the kidney nourishment method promotes blood circulation and the blood circulation promotion method is applied to enhance the kidney nourishment, and furthermore, the kidney nourishment method and the blood circulation promotion method are mutually cooperated. The preparation has the advantage of unique inventive concept and obvious treatment effect on treating various diseases caused by kidney deficiency and blood stasis. The natural plants special in Yunnan province are used as raw materials which are easy to obtain and has low cost, and the preparation has good development and application prospects.
FIELD: medicine, cosmetology, vitamins. SUBSTANCE: invention proposes lotion comprising: (a) therapeutically effective amount of active vitamin D 3 ; (b) component of oily phase comprising solid oily component comprising white vaseline and higher alcohol and liquid oily component comprising squalan also; (c) component of an aqueous phase comprising ionic polysaccharide; (d) nonionic surface-active substance; (1) content of indicated ionic polysaccharide is from 0.3 to 1.0 weight part of total weight of preparation; (2) content of indicated higher alcohol is from 0.2 to 1.0 weight part of total weight of preparation; (3) HLB value of indicated nonionic surface-active substance is 10 or above. Lotion is suitable for application of hair sites exhibiting the satisfactory pharmacological activity, stability of basic medicinal component and physical stability. Invention can be used in pharmacology and cosmetology for preparing pharmaceutical composition. EFFECT: valuable medicinal and cosmetic properties of lotion. 7 cl, 15 tbl, 2 dwg, 12 ex
FIELD: medicine, veterinary science. ^ SUBSTANCE: group of inventions concerns veterinary medicine. An immunogenic dose of the immunogenic material Mycoplasma hyopneumoniae and an immunogenic dose of live attenuated PRRS virus are used for producing a vaccine for combined introduction of the Mycoplasma hyopneumoniae vaccine and the PRRSV vaccine to Mycoplasma hyopneumoniae primed pigs. The immunogenic material Mycoplasma hyopneumoniae and live attenuated PRRS virus either can be, or are either in a common container, or in separate containers, and either mixed before introduction, or introduced consistently within no more than 24 hours. The method of pigs' vaccination implies the stages of primary vaccination (priming) with the Mycoplasma hyopneumoniae vaccine followed with combined vaccination with the immunogenic material Mycoplasma hyopneumoniae and live attenuated PRRS virus with the components Mycoplasma hyopneumoniae and PRRS being introduced consistently within no more than 24 hours. ^ EFFECT: group of inventions allows higher efficacy of mycoplasmosis and PRRSV vaccination in pigs. ^ 6 cl, 2 ex
One hundred and twenty-four patients suffering from major depressive disorder will be randomized to participate in 16 sessions of either supportive-expressive therapy or emotion-focused therapy. The two treatments are theorized to differ in their main mechanism of change: supportive-expressive therapy places emphasis on insight as its main mechanism of change, and emotion-focused therapy places emphasis on emotional processing as its main mechanism of change. Both can serve as strength- or weakness-focused treatments, based on the patient's baseline levels of insight and emotional processing. Importantly, this study will employ multiple complementary methods, which will include session-by-session self-report questionnaires from both patient and therapist, as well as interdisciplinary measures based on hormonal and acoustic measures, cognitive tasks, clinician interviews, and behavioral coding systems to complement the self-report measures. In addition, prior the beginning of treatment patients will complete diaries via mobile survey application. The findings will contribute to the research on personalized mechanisms of change and can help clinicians focus on more efficient treatment delivery, adapted to given subpopulations of patients, according to their strengths and weaknesses. If a mechanism most likely to stimulate change for a subpopulation is identified, a corresponding treatment can be chosen that is most likely to activate that particular mechanism and by that improve the rate of patients' respondent to treatment.
The World Health Organization recommends that older adults undertake at least 150 minutes of moderate intensity physical activity over the course of each week in order to maintain physical, mental, and social health. This goal turns out to be very difficult for most community dwelling older adults to achieve, due to both actual and perceived barriers. These barriers include personal health limitations, confinement issues, and self-imposed restrictions such as fear of injury. Climate change exacerbates the confinement issues and injury fears among the elderly. To assist older adults in obtaining the benefits of increased physical activity under increasingly challenging climate conditions, we propose a targeted non-volitional intervention which could serve as a complement to volitional physical activity. Exogenous neuro-muscular stimulation of the soleus muscles is a non-invasive intervention capable of significantly increasing cardiac output in sedentary individuals. Long-term daily use has been shown to improve sleep, reduce bone loss, and reverse age-related cognitive decline, all of which are significant health concerns for older adults. These outcomes support the potential benefit of exogenous neuro-muscular stimulation as a complementary form of physical activity which older adults may find convenient to incorporate into their daily life when traditional forms of exercise are difficult to achieve due to barriers to completing traditional physical activities as a result of in-home or in-bed confinement, perceptual risks, or real environmental risks such as those arising from climate change.
Melatonin, which can be produced in the skin, exerts a protective effect against damage induced by ultraviolet radiation (UVR). The present study investigated the effect of UVB, the most damaging component of UVR, on melatonin metabolism in HaCaT keratinocytes and in a cell-free system. Four metabolites were identified by HPLC and LC-MS: 6-hydroxymelatonin, AFMK, 2-hydroxymelatonin (the main intermediate between melatonin and AFMK) and 4-hydroxymelatonin. Concentrations of these photoproducts were directly proportional to UVR-dose and to melatonin substrate content, and their accumulation was time dependent. The UVR-dependent increase of AFMK and 2-hydroxymelatonin was also detected in keratinocytes, where it was accompanied by simultaneous consumption of intracellular melatonin. Of note, melatonin and its two major metabolites, 2-hydroxymelatonin and AFMK, were also detected in untreated keratinocytes, neither irradiated nor preincubated with melatonin. Thus, intracellular melatonin metabolism is enhanced under exposure to UVR. The additional biological activity of these individual melatonin metabolites increases the spectrum of potential actions of the recently identified cutaneous melatoninergic system.
FIELD: medicine, pharmacy. SUBSTANCE: drug containing heparin, anesthesin, emulsifier and purified water has additionally base and made as suppository at the following ratio of components, g per one suppository: heparin, 0.006-0.01; anesthesin, 0.04-0.06; purified water, 0.016-0.023; emulsifier, up to 5% of base mass and base, the balance, to make suppository by mass, 1.15-1.45 g. Base consists of solid confectionery fat based on plasticized hydrogenated fat or mixture of mono-, di- and triglycerides of natural saturated fatty acids with length of carbon chain C 12 -C 18 . Invention provides possibility of using the proposed medicinal agent "Nigepan" in acute external and internal hemorrhoidal nodes and in acute inflammatory pain anal syndrome. Also, they can be used in complex treatment. Preparation shows good tolerance and can be used in all forms of sicknesses. EFFECT: enhanced effectiveness of drug. 2 cl, 3 tbl
A herbal pack structure for improving nasal inflammation includes a bag and a compound herbal prescription. The bag has a containing space, with a plurality of pores on the periphery of the bag and in communication with the containing space. The bag includes an opening portion connected with the containing space, and a seal portion near the opening portion for sealing the containing space. The compound herbal prescription is filled into the containing space and includes a first category and a second category of herbals. The first category includes Blumea balsamifera, peppermint, Houttuynia cordata, and Small Centipeda. The second category includes Climbing Violet and Large Smooth Ixeris. The compound herbal prescription are heated by microwave for generating an extract product. The bag is applied on the face around the nasal cavity for improving nasal inflammation and restoring the smoothness of breath.